Biotech Regulatory Clearances and Edge AI Pivots Prompt Capital Reallocation Across US EquitiesGlobal Report·22 hours agoBDRX-1.79%MASK+1.97%
Inside the Biotech Sector's Recent Clinical Catalyst WaveGlobal Report·1 day ago, 04:17 AMGENB-3.11%IBRX-4.05%
monday.com's AI Pivot and Tron's Token Buildup Highlight Small-Cap RealignmentsGlobal Report·1 day ago, 04:14 AMMNDY+7.93%MWC+4.67%
The 2026 Biotech Divide: When Generative Biology Meets the FDA WallGlobal Report·2 days ago, 04:13 AMINM-7.57%TXG-3.72%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 22 at 04:05 PMZYBT-3.89%CYH-1.80%
Biodexa seeks shareholder approval to adopt new articles of association for E deferred sharesPUBT·Jul 9 at 03:16 PMBDRX-1.79%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jul 6 at 07:05 AMUPC-10.55%LUCY-6.40%
Biodexa prices $1 million private placement of pre-funded warrants at $2.85 per ADSPUBT·Jun 30 at 07:38 AMBDRX-1.79%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jun 30 at 07:05 AMUPC-10.55%DCOY+2.02%
Biodexa Pharmaceuticals shares are trading lower after the company announced the pricing of its $3.5 million offering and concurrent private placement of pre-funded warrants and warrants.benzinga_article·Jun 30 at 07:04 AMBDRX-1.79%
Biodexa to issue Series M, N and O warrants with $2.85 exercise price pending shareholder approvalPUBT·Jun 30 at 07:03 AMBDRX-1.79%
Biodexa wins Health Canada approval to expand Serenta Phase 3 FAP trial into CanadaPUBT·Jun 29 at 07:30 AMBDRX-1.79%
